CN116898921B - Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation - Google Patents
Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation Download PDFInfo
- Publication number
- CN116898921B CN116898921B CN202311004549.3A CN202311004549A CN116898921B CN 116898921 B CN116898921 B CN 116898921B CN 202311004549 A CN202311004549 A CN 202311004549A CN 116898921 B CN116898921 B CN 116898921B
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- traditional chinese
- percolating
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 241000334160 Isatis Species 0.000 title abstract description 5
- 240000001398 Typha domingensis Species 0.000 title abstract description 4
- 238000000855 fermentation Methods 0.000 claims abstract description 30
- 230000004151 fermentation Effects 0.000 claims abstract description 30
- 238000000605 extraction Methods 0.000 claims abstract description 10
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 7
- 241000612118 Samolus valerandi Species 0.000 claims abstract description 7
- 238000005325 percolation Methods 0.000 claims abstract description 7
- 239000003607 modifier Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 16
- 230000001580 bacterial effect Effects 0.000 claims description 15
- ZQEBQGAAWMOMAI-SSDOTTSWSA-N (2r)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(O)=O ZQEBQGAAWMOMAI-SSDOTTSWSA-N 0.000 claims description 11
- 230000004087 circulation Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 claims description 9
- 241000245665 Taraxacum Species 0.000 claims description 7
- JATPLOXBFFRHDN-DDWIOCJRSA-N [(2r)-2-acetyloxy-3-carboxypropyl]-trimethylazanium;chloride Chemical compound [Cl-].CC(=O)O[C@H](CC(O)=O)C[N+](C)(C)C JATPLOXBFFRHDN-DDWIOCJRSA-N 0.000 claims description 7
- 239000010231 banlangen Substances 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 241000194108 Bacillus licheniformis Species 0.000 claims description 5
- 241000235342 Saccharomycetes Species 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000011049 filling Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 230000035484 reaction time Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000009736 wetting Methods 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 240000001949 Taraxacum officinale Species 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000050051 Chelone glabra Species 0.000 abstract 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000243 solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000008961 swelling Effects 0.000 description 7
- 210000005069 ears Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 6
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 4
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 4
- 229930016920 cichoric acid Natural products 0.000 description 4
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 4
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010017553 Furuncle Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010052369 Encephalitis lethargica Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000002021 butanolic extract Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 201000002498 viral encephalitis Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 102100029368 Cytochrome P450 2C18 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 240000003409 Gentiana lutea Species 0.000 description 1
- 235000002873 Gentiana lutea Nutrition 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000976416 Isatis tinctoria subsp. canescens Species 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000405217 Viola <butterfly> Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000010829 isocratic elution Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/86—Violaceae (Violet family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a preparation method of a cattail blue compound traditional Chinese medicine preparation, which comprises four traditional Chinese medicines of dandelion, isatis root, bunge corydalis herb and baical skullcap root, wherein a certain modifier is added to the traditional Chinese medicine raw materials by a pressurized percolation extraction method for improving the absorption of lipophilic substances in flavone components, and the antibacterial and anti-inflammatory effects are improved by adding proper substances in the fermentation process to enhance the absorption of medicines without being metabolized, and the stability of the preparation is improved by enhancing the structure of volatile substances.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine preparations, in particular to extraction of traditional Chinese medicine raw materials and improvement of active ingredients, and specifically relates to a preparation method of a cattail-basket compound traditional Chinese medicine preparation.
Background
The cattail herba is composed of four traditional Chinese medicines of dandelion, radix isatidis, herba violae and radix scutellariae, and has the effects of clearing heat, detoxicating, resisting inflammation and reducing swelling. Dandelion herb and Chinese medicine name. Aliases herba Violae, grandma, hua Hualang, etc. Perennial herb of Compositae. Bitter, sweet and cold in nature. It is mainly used for treating furuncle, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, pulmonary abscess, appendicitis, jaundice due to damp-heat, stranguria due to heat, etc.
Radix Isatidis is the dry root of Isatis tinctoria L of Brassicaceae. Mainly treats influenza, epidemic encephalitis B, pneumonia, erysipelas, heat toxin spots, coma, epistaxis, pharyngeal swelling, mumps, fire eyes, sore rash, dark purple tongue, pharyngitis, throat sore and skin disease, plague of large head, carbuncle and swelling; can be used for preventing and treating epidemic encephalitis B, acute and chronic hepatitis, epidemic parotitis, and osteomyelitis.
The herba Violae is herba Violae of Viola; the bag of Leguminosae plant Rice, semen Setariae bag or root-carrying whole plant of Gentiana lutea of Gentianaceae. Clearing heat and promoting diuresis, removing toxic substances and relieving swelling. For furuncle, carbuncle, swelling, scrofula, jaundice, dysentery, diarrhea, conjunctival congestion, pharyngitis and snake bite.
Radix Scutellariae, called radix Camelliae Japonicae, is perennial herb of Scutellaria of Labiatae; the radix scutellariae grows on sunny grass slopes. It has the effects of clearing heat, eliminating dampness, purging pathogenic fire, removing toxic substances, stopping bleeding, and preventing miscarriage. Is used for treating warm diseases, upper respiratory infection, cough due to lung heat, jaundice due to damp-heat, pneumonia, dysentery, hemoptysis, conjunctival congestion, fetal irritability, hypertension, carbuncle, furuncle, and sore. The radix scutellariae has good clinical antibacterial property and does not generate drug resistance.
The commercial Pu Di lan is clinically used, and although the curative effect is definite, the curative effect is slow, mainly because the concentration of the effective components in the commercial Pu Di lan is low, the efficacy is still to be further improved, so that the effective components are respectively improved by adopting a proper extraction mode for the traditional Chinese medicine raw materials, and the improvement of the absorption and the efficacy of the traditional Chinese medicine is the focus of the research of the invention.
Disclosure of Invention
In order to solve the technical problems, the specific preparation process of the invention comprises the following steps:
(1) Pressurized percolation
A. cleaning 9-13 parts of dandelion and 9-13 parts of bunge corydalis herb, drying, crushing and sieving with a 100-mesh sieve;
b. wetting and expanding the crushed materials and 70% ethanol solvent according to the mass ratio of 1:1, stirring for 10-20min, standing for 15-30min, filling the wetted materials into a percolating tank in pressurized percolating equipment, adding 10-12 parts of 50% ethanol solution into the percolating tank, regulating the pressure to 5-7Mpa, the percolating flow rate to 4-8ml/min, and collecting bottom effluent filtrate into the percolating tank through a filter;
c. Heating the percolate tank in 70-80deg.C water bath for 30-40min, volatilizing alcohol, adding into a microwave tank, adding 1-3 parts of modifier, reacting at 40-60deg.C and microwave power of 10-15w for 10-15min to obtain filtrate A;
wherein the modifier is acetyl L-carnitine hydrochloride;
(2) Fermentation extraction
D. Taking 8-12 parts of radix isatidis and 6-8 parts of radix scutellariae, cleaning with deionized water for 4-6 times, draining off water, and drying at 50-60 ℃ until the weight is constant to obtain a fermentation material;
e. preparing a compound bacterial liquid: firstly, adding 1-3 parts of additive into 50 parts of water, mixing to prepare a solvent, then adding 1 part of lactobacillus, 1 part of saccharomycete and 1 part of bacillus licheniformis, and uniformly stirring to obtain a compound bacterial liquid;
f. Placing the fermentation material into a compound bacterial solution, fermenting for 3-5d under the condition of pH=4-7 at 40-50 ℃, and filtering and sterilizing to obtain a fermentation filtrate B;
wherein the additive is L-ornithine hydrochloride
(3) Mixing
Mixing the filtrate A and the fermentation filtrate B according to the mass ratio of 1:1, preserving for 12-16 hours at the low temperature environment of 4-10 ℃, then adopting ultrasonic treatment to combine with a nozzle circulation system, dropwise adding 0.8-1.2 parts of accelerator into the mixture, wherein the ultrasonic power is 100-150w, the circulation flow rate is 25-40L/min, the reaction time is 40-60min, and recovering to room temperature to obtain the traditional Chinese medicine preparation;
wherein the promoter is N-t-butoxycarbonyl-D-proline.
The invention has the beneficial effects that:
1) The dandelion and the bunge corydalis herb raw materials are subjected to a pressurized percolation extraction method, so that the solvent can easily infiltrate into the tissue of the medicinal materials under the action of a large pressure to dissolve the internal components of the medicinal materials, the concentration in the tissue is large, the outward diffusion speed is also high, and the extraction of the components is facilitated; the microwave treatment can promote the dissolution of partial insoluble components through the thermal effect and the physical effect, and can accelerate the dissolution of active components in the traditional Chinese medicine preparation, thereby improving the bioavailability; absorption and transport of the drug is also more efficient when it dissolves and is released into the body more rapidly.
2) The extracting solution is modified in a microwave heating mode, on one hand, acetyl L-carnitine hydrochloride preferentially reacts with lipophilic substances, so that flavonoid lipophilic substances in the traditional Chinese medicine component are connected with acetyl and hydroxyl in the acetyl L-carnitine hydrochloride, and the absorption of the flavonoid lipophilic substances in the traditional Chinese medicine component is facilitated; on the other hand, the modified substance promotes the transportation of CRP and P-gp transport proteins of the intestinal epithelial cells, thereby improving the absorption rate and rapidly achieving the therapeutic effect.
3) The method has the advantages that the contents of active ingredients in the isatis roots and the baikal skullcap roots can be improved firstly by using a fermentation mode, the synergistic effect between the active ingredients in the isatis roots and the baikal skullcap roots can be promoted, the drug effect can be improved, more polypeptides and amino acids are generated in the fermentation process by adding L-ornithine hydrochloride in the fermentation process, and the synergistic effect of various active substances can lead cytokines such as IL-6, TNF-alpha and the like to polarize TAMs through NF- κB signal paths and convert the polarized TAMs into M1, so that the functions of anti-inflammatory, antibacterial and immunoregulation are enhanced, and the synergistic effect on a plurality of targets can avoid drug resistance.
4) The L-ornithine hydrochloride can play a competitive inhibition role, and can play a role in inhibiting CYP3A and CYP2C in isozymes with the most abundant CYP450 enzyme content in the small intestine, so that the CYP3A4 and P-gp are inhibited to increase the probability of medicament metabolism in a synergistic mode, the bioavailability of the medicament is reduced, the circulation of the medicament in the body is accelerated, and the treatment effect is quickly and effectively achieved through blood circulation.
5) The stability of the N-t-butoxycarbonyl-D-proline is high, the activity is good in a low-temperature environment, the generation of organic acid can be catalyzed by combining an improved process in the low-temperature environment, the pH value of the preparation is reduced, on one hand, the organic acid inhibits the growth of harmful microorganisms, the multiple double bonds and the rigid structure in the N-t-butoxycarbonyl-D-proline can also participate in improving the volatile oil component in the low-temperature environment, and the organic acid component, the N-t-butoxycarbonyl-D-proline and the volatile oil form a stable structure of ester or acid salt, so that the biological activity is improved, the volatile oil component is retained to the greatest extent, the activity and stability of the volatile oil component are improved, and the curative effect and tolerance of the medicine are improved; the organic acid component also gives the special taste and texture characteristics to the traditional Chinese medicine fermentation liquor; on the other hand, the tert-butoxycarbonyl in N-tert-butoxycarbonyl-D-proline is a good protecting group, and can also protect the active ingredients in the preparation from being damaged and deactivated when the acidity in the preparation is higher.
6) The preparation in low temperature environment can be firstly crushed by shaking macromolecular substances or salt substances which are separated out in low temperature, on the other hand, the occurrence of side reaction is reduced in low temperature environment, and more generated organic acid can play a role in stabilizing the volatile oil unstable components, so that the reaction interface is increased by ultrasonic treatment, the energy transfer between the volatile oil unstable components is promoted, and the stability of the preparation is improved.
Detailed Description
The present invention will be described in further detail with reference to examples.
All the traditional Chinese medicine raw materials used in the embodiment of the invention are purchased by Jiangxi Jie Chengjie medicinal wholesale Limited company, and the rest raw materials or chemical reagents are obtained through conventional commercial paths if no special description exists.
Example 1
(1) Pressurized percolation
A. cleaning, drying and crushing 11 parts of dandelion and 11 parts of bunge corydalis herb, and sieving the mixture through a 100-mesh sieve;
b. Wetting and expanding the crushed materials and 70% ethanol solvent according to the mass ratio of 1:1, standing for 22min, filling the wetted materials into a percolating tank in pressurized percolating equipment, adding 11 parts of 50% ethanol solution into the percolating tank, regulating the pressure to 6Mpa, percolating at the flow rate of 6ml/min, and collecting bottom effluent filtrate into the percolating tank through a filter;
c. heating the percolate tank in a water bath at 75 ℃ for 35min, adding the percolate tank into a microwave tank after alcohol volatilizes, adding 2 parts of acetyl L-carnitine hydrochloride at 50 ℃ and microwave power of 12w, and reacting for 12min to obtain a filtrate A;
(2) Fermentation extraction
D. taking 10 parts of radix isatidis and 7 parts of radix scutellariae, washing with deionized water for 5 times, draining off water, and drying at 55 ℃ until the weight is constant to obtain a fermentation material;
e. Preparing a compound bacterial liquid: firstly, adding 2 parts of L-ornithine hydrochloride into 50 parts of water, mixing to prepare a solvent, then adding 1 part of lactic acid bacteria, 1 part of saccharomycetes and 1 part of bacillus licheniformis, and uniformly stirring to obtain a compound bacterial solution;
f. Placing the fermentation material in the compound bacterial liquid, fermenting for 4d under the condition of pH=6 at 40-50 ℃, and filtering and sterilizing to obtain fermentation filtrate B;
(3) Mixing
Mixing the filtrate A and the fermentation filtrate B according to the mass ratio of 1:1, preserving for 14 hours at the low temperature environment of 6 ℃, then adopting ultrasonic treatment to combine with a nozzle circulation system, dropwise adding 1 part of N-tert-butoxycarbonyl-D-proline into the mixture, wherein the ultrasonic power is 120w, the circulation flow rate is 32L/min, the reaction time is 50min, and recovering to room temperature to obtain the traditional Chinese medicine preparation;
Example 2
(1) Pressurized percolation
A. Cleaning 9 parts of dandelion and 13 parts of bunge corydalis herb, drying, crushing and sieving with a 100-mesh sieve;
b. wetting and expanding the crushed materials and 70% ethanol solvent according to the mass ratio of 1:1, standing for 30min, filling the wetted materials into a percolating tank in pressurized percolating equipment, adding 12 parts of 50% ethanol solution into the percolating tank, regulating the pressure to 5Mpa, percolating at the flow rate of 4ml/min, and collecting bottom effluent filtrate into the percolating tank through a filter;
c. Heating the percolate tank in water bath at 70 ℃ for 30min, adding the percolate tank into a microwave tank after alcohol volatilizes, adding 3 parts of acetyl L-carnitine hydrochloride at 40 ℃ and microwave power of 15w, and reacting for 10min to obtain filtrate A;
(2) Fermentation extraction
D. Taking 12 parts of radix isatidis and 6 parts of radix scutellariae, washing with deionized water for 4 times, draining off water, and drying at 50 ℃ until the weight is constant to obtain a fermentation material;
e. Preparing a compound bacterial liquid: firstly, adding 1 part of L-ornithine hydrochloride into 50 parts of water, mixing to prepare a solvent, then adding 1 part of lactic acid bacteria, 1 part of saccharomycetes and 1 part of bacillus licheniformis, and uniformly stirring to obtain a compound bacterial solution;
f. placing the fermentation material in a compound bacterial solution, fermenting for 3d at 40 ℃ and pH=7, and filtering and sterilizing to obtain a fermentation filtrate B;
(3) Mixing
Mixing the filtrate A and the fermentation filtrate B according to the mass ratio of 1:1, preserving for 12 hours at the low temperature environment of 10 ℃, then adopting ultrasonic treatment to combine with a nozzle circulation system, dropwise adding 0.8 part of N-t-butoxycarbonyl-D-proline into the mixture, wherein the ultrasonic power is 150w, the circulation flow rate is 40L/min, the reaction time is 60min, and the mixture is recovered to the room temperature to obtain the traditional Chinese medicine preparation;
Example 3
(1) Pressurized percolation
A. cleaning 13 parts of dandelion and 9 parts of bunge corydalis herb, drying, crushing and sieving with a 100-mesh sieve;
b. Wetting and expanding the crushed materials and 70% ethanol solvent according to the mass ratio of 1:1, standing for 15min, filling the wetted materials into a percolating tank in pressurized percolating equipment, adding 10 parts of 50% ethanol solution into the percolating tank, regulating the pressure to 7Mpa, controlling the percolating flow rate to 8ml/min, and collecting bottom effluent filtrate into the percolating tank through a filter;
c. Heating the percolate tank in water bath at 80 ℃ for 40min, adding the percolate tank into a microwave tank after alcohol volatilizes, adding 1 part of acetyl L-carnitine hydrochloride at 60 ℃ and microwave power of 10w, and reacting for 15min to obtain filtrate A;
(2) Fermentation extraction
D. taking 8 parts of radix isatidis and 8 parts of radix scutellariae, washing with deionized water for 6 times, draining off water, and drying at 60 ℃ until the weight is constant to obtain a fermentation material;
e. Preparing a compound bacterial liquid: firstly, adding 3 parts of L-ornithine hydrochloride into 50 parts of water, mixing to prepare a solvent, then adding 1 part of lactic acid bacteria, 1 part of saccharomycetes and 1 part of bacillus licheniformis, and uniformly stirring to obtain a compound bacterial solution;
f. placing the fermentation material in a compound bacterial solution, fermenting for 5 days at 50 ℃ and under the condition of pH=4, and filtering and sterilizing to obtain a fermentation filtrate B;
(3) Mixing
Mixing the filtrate A and the fermentation filtrate B according to the mass ratio of 1:1, preserving for 16 hours at the low temperature environment of 4 ℃, then adopting ultrasonic treatment to combine with a nozzle circulation system, dropwise adding 1.2 parts of N-t-butoxycarbonyl-D-proline into the mixture, wherein the ultrasonic power is 100w, the circulation flow rate is 25L/min, the reaction time is 40min, and recovering to room temperature to obtain the traditional Chinese medicine preparation;
Comparative example 1
This comparative example differs from example 1 in that the acetyll-carnitine hydrochloride in step (1) is palmitic acid, and the other embodiments are the same as example 1.
Comparative example 2
This comparative example differs from example 1 in that the acetyll-carnitine hydrochloride in step (1) is methylformamide, and the remaining embodiments are the same as example 1.
Comparative example 3
This comparative example differs from example 1 in that the L-ornithine hydrochloride in step (2) is hydrochloric acid, and the remaining embodiments are the same as example 1.
Comparative example 4
This comparative example differs from example 1 in that L-ornithine hydrochloride in step (2) is an amino acid, and the other embodiments are the same as example 1.
Comparative example 5
This comparative example differs from example 1 in that the N-t-butoxycarbonyl-D-proline in step (3) is hydroxypropyl methylcellulose and the remaining embodiments are the same as example 1.
Comparative example 6
This comparative example differs from example 1 in that the N-t-butoxycarbonyl-D-proline in step (3) is sodium carboxymethyl cellulose and the remaining embodiments are the same as example 1.
The evaluation method comprises the following steps:
(1) Chromatographic content determination: the main component of Pu Di lan was measured by high performance liquid chromatography (Chinese pharmacopoeia 2020 edition). Octadecylsilane chemically bonded silica is used as a filler, acetonitrile-water (volume ratio is 32:68) is used for isocratic elution; the theoretical plate number should be not less than 2000 calculated on the astragaloside peak.
Preparation of a control solution: taking appropriate amount of astragaloside and chicoric acid reference substances, precisely weighing, and adding methanol to prepare a solution containing 0.4mg per 1 mL.
Preparation of test solution: precisely measuring 20mL of the product, extracting with water saturated n-butanol for 5 times under shaking, each time 25mL, mixing n-butanol extract, washing with ammonia test solution for 3 times, each time 20mL, recovering n-butanol extract, dissolving residues in methanol, transferring to a 10mL measuring flask, adding methanol to scale, shaking, centrifuging, and collecting supernatant.
Assay: respectively precisely sucking 20 μl of control solution and 20 μl of sample solution, and injecting into liquid chromatograph for measurement to obtain the contents of astragaloside and chicoric acid. The results of the measurement of the active ingredients are shown in Table 1.
TABLE 1 determination of the content of Astragaloside and chicoric acid
Group of | Astragaloside content mg/mL | Chicoric acid content mg/mL |
Example 1 | 52.82 | 0.67 |
Example 2 | 49.55 | 0.64 |
Example 3 | 48.83 | 0.63 |
Comparative example 1 | 40.73 | 0.56 |
Comparative example 2 | 42.54 | 0.47 |
Comparative example 3 | 35.76 | 0.41 |
Comparative example 4 | 32.62 | 0.49 |
Comparative example 5 | 38.71 | 0.42 |
Comparative example 6 | 35.28 | 0.41 |
(2) Pharmacological experimental study for resisting acute inflammation of mice
80 KM mice, male, weighing about 25g, were prepared, and randomly divided into 10 groups of 8 animals each, blank groups, examples 1-3 groups, and comparative examples 1-6 groups. The respective liquid medicines of 0.21mL/10g body weight were administered to the groups of examples 1 to 3 and the groups of comparative examples 1 to 6, and the blank group was administered with an equal amount of physiological saline. Each group was administered 1 time a day, 3d continuously, and after 1h last administration, the mice of each group except the blank group were uniformly smeared with 0.04mL of xylene on the front and back sides of the left ear, and the right ear was used as a control. Mice were sacrificed 30min after inflammation, two ears were cut off along the auricle edge, the same positions were punched out with a direct 9mm punch, the analytical balance was weighed, the difference in weight of the left and right ears was the swelling degree, and the swelling inhibition rate was calculated and expressed as the anti-inflammatory strength of the drug. The results are shown in Table 2 below.
Inhibition ratio = (difference in weight of both ears of blank group-difference in weight of both ears of administration group)/difference in weight of both ears of blank group×100%
Table 2 effect of drug on ear swelling in mice due to xylene (x±s, n=10)
Group of | Left ear weight/mg | Right ear weight/mg | Weight difference of two ears/mg | Inhibition/% |
Blank group | 24.0±1.8 | 9.3±0.8 | 14.7±1.9 | |
Example 1 | 14.9±1.6 | 8.7±0.7 | 6.2±1.9** | 57.8 |
Example 2 | 15.9±1.4 | 9.1±0.8 | 6.8±1.8** | 53.7 |
Example 3 | 16.1±1.3 | 8.9±0.6 | 7.2±1.1* | 51.0 |
Comparative example 1 | 18.2±0.9 | 9.1±0.8 | 9.1±1.6 | 38.0 |
Comparative example 2 | 17.4±1.1 | 9.2±0.5 | 8.2±1.2 | 44.2 |
Comparative example 3 | 18.1±1.2 | 9.4±0.7 | 8.7±1.5 | 40.8 |
Comparative example 4 | 17.2±1.0 | 9.3±0.8 | 7.9±1.2 | 46.2 |
Comparative example 5 | 17.5±0.9 | 9.2±0.7 | 8.3±1.0 | 43.5 |
Comparative example 6 | 18.3±1.2 | 9.3±0.8 | 9.0±1.1 | 38.7 |
P <0.01, P <0.05 compared to the blank.
Claims (1)
1. A preparation method of a cattail-basket compound traditional Chinese medicine preparation is characterized by comprising the following steps:
The preparation process comprises the following steps:
(1) Pressurized percolation
A. cleaning 9-13 parts of dandelion and 9-13 parts of bunge corydalis herb, drying, crushing and sieving with a 100-mesh sieve;
b. wetting and expanding the crushed materials and 70% ethanol solvent according to the mass ratio of 1:1, stirring for 10-20min, standing for 15-30min, filling the wetted materials into a percolating tank in pressurized percolating equipment, adding 10-12 parts of 50% ethanol solution into the percolating tank, regulating the pressure to 5-7Mpa, the percolating flow rate to 4-8ml/min, and collecting bottom effluent filtrate into the percolating tank through a filter;
c. Heating the percolate tank in 70-80deg.C water bath for 30-40min, volatilizing alcohol, adding into a microwave tank, adding 1-3 parts of modifier, reacting at 40-60deg.C and microwave power of 10-15w for 10-15min to obtain filtrate A;
(2) Fermentation extraction
D. Taking 8-12 parts of radix isatidis and 6-8 parts of radix scutellariae, cleaning with deionized water for 4-6 times, draining off water, and drying at 50-60 ℃ until the weight is constant to obtain a fermentation material;
e. preparing a compound bacterial liquid: firstly, adding 1-3 parts of additive into 50 parts of water, mixing to prepare a solvent, then adding 1 part of lactobacillus, 1 part of saccharomycete and 1 part of bacillus licheniformis, and uniformly stirring to obtain a compound bacterial liquid;
f. Placing the fermentation material into a compound bacterial solution, fermenting for 3-5d under the condition of pH=4-7 at 40-50 ℃, and filtering and sterilizing to obtain a fermentation filtrate B;
(3) Mixing
Mixing the filtrate A and the fermentation filtrate B according to the mass ratio of 1:1, preserving for 12-16 hours at the low temperature environment of 4-10 ℃, then adopting ultrasonic treatment to combine with a nozzle circulation system, dropwise adding 0.8-1.2 parts of accelerator into the mixture, wherein the ultrasonic power is 100-150w, the circulation flow rate is 25-40L/min, the reaction time is 40-60min, and recovering to room temperature to obtain the traditional Chinese medicine preparation;
the modifier in the step (1) is acetyl L-carnitine hydrochloride;
the additive in the step (2) is L-ornithine hydrochloride;
the promoter in the step (3) is N-t-butoxycarbonyl-D-proline.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311004549.3A CN116898921B (en) | 2023-08-10 | 2023-08-10 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311004549.3A CN116898921B (en) | 2023-08-10 | 2023-08-10 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116898921A CN116898921A (en) | 2023-10-20 |
CN116898921B true CN116898921B (en) | 2024-05-31 |
Family
ID=88367900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311004549.3A Active CN116898921B (en) | 2023-08-10 | 2023-08-10 | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116898921B (en) |
Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943633A (en) * | 2005-10-09 | 2007-04-11 | 董斌 | Pudilan antiphlogistic granules and its Pudilan antiphlogistic granules prepared by said method |
WO2007059649A1 (en) * | 2005-11-25 | 2007-05-31 | Zhiquan Zhao | Chinese pharmaceutical compositions for treating upper respiratory tract infection and processes for preparation thereof |
CN101401921A (en) * | 2008-10-30 | 2009-04-08 | 河南省龙腾高科实业有限公司 | Microbial ecological traditional Chinese medicine preparation for livestock and poultry from fermentation production of multiple bacterials and fermentation method thereof |
KR20120125042A (en) * | 2011-05-06 | 2012-11-14 | 김영욱 | A process for preparing a fermented broth of herbal medicine by combined microorganisms, a fermented broth prepared by the process, and a fermented food prepared by the fermented broth |
KR20140028305A (en) * | 2012-08-28 | 2014-03-10 | 김영욱 | A fermentation medicinal herbs extract process |
CN103704483A (en) * | 2013-12-31 | 2014-04-09 | 株洲千金药业股份有限公司 | Feed fermented by utilizing traditional Chinese medicine drugs and preparation method of feed |
CN104523943A (en) * | 2014-12-29 | 2015-04-22 | 河南天纳图生物科技有限公司 | Compound fermentation type traditional Chinese medicine for preventing and treating multiple seasonal febrile diseases of livestock and poultry |
CN104983805A (en) * | 2015-07-21 | 2015-10-21 | 哈尔滨市龙生北药生物工程股份有限公司 | Preparation method of Pudilan anti-inflammatory tablet |
CN106361905A (en) * | 2016-08-30 | 2017-02-01 | 福建贝迪药业有限公司 | Compound Chinese herbal microecological preparation with efficacies of supporting right and resolving toxins for beasts and birds and preparation method of compound Chinese herbal microecological preparation |
CN106389562A (en) * | 2016-11-30 | 2017-02-15 | 河南牧翔动物药业有限公司 | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method |
CN106913627A (en) * | 2017-03-20 | 2017-07-04 | 济川药业集团有限公司 | A kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof |
CN106913516A (en) * | 2017-03-10 | 2017-07-04 | 南京安吉生物科技有限公司 | A kind of blue syrup in Pu ground and its production and use |
CN106913717A (en) * | 2017-03-10 | 2017-07-04 | 南京安吉生物科技有限公司 | The preparation method and purposes of a kind of Pu bring down a fever piece |
CN107319546A (en) * | 2017-08-07 | 2017-11-07 | 黑龙江省兽医科学研究所 | A kind of fermented tcm powder and preparation method thereof |
CN107889942A (en) * | 2017-12-04 | 2018-04-10 | 大工(青岛)新能源材料技术研究院有限公司 | Fermentative feedstuff of microbe and preparation method thereof |
CN109718269A (en) * | 2019-03-01 | 2019-05-07 | 江西农业大学 | A kind of Chinese medicine microecological preparation and preparation method thereof |
CN110663818A (en) * | 2019-08-23 | 2020-01-10 | 内蒙古农业大学 | Fermented dandelion feed additive and preparation method and application thereof |
CN112237594A (en) * | 2019-07-18 | 2021-01-19 | 济川药业集团有限公司 | Pharmaceutical composition, Pudilan buccal tablet and preparation method thereof |
WO2022022020A1 (en) * | 2020-07-30 | 2022-02-03 | 江苏康缘药业股份有限公司 | Traditional chinese medicine composition, preparation method and use |
-
2023
- 2023-08-10 CN CN202311004549.3A patent/CN116898921B/en active Active
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1943633A (en) * | 2005-10-09 | 2007-04-11 | 董斌 | Pudilan antiphlogistic granules and its Pudilan antiphlogistic granules prepared by said method |
WO2007059649A1 (en) * | 2005-11-25 | 2007-05-31 | Zhiquan Zhao | Chinese pharmaceutical compositions for treating upper respiratory tract infection and processes for preparation thereof |
CN101401921A (en) * | 2008-10-30 | 2009-04-08 | 河南省龙腾高科实业有限公司 | Microbial ecological traditional Chinese medicine preparation for livestock and poultry from fermentation production of multiple bacterials and fermentation method thereof |
KR20120125042A (en) * | 2011-05-06 | 2012-11-14 | 김영욱 | A process for preparing a fermented broth of herbal medicine by combined microorganisms, a fermented broth prepared by the process, and a fermented food prepared by the fermented broth |
KR20140028305A (en) * | 2012-08-28 | 2014-03-10 | 김영욱 | A fermentation medicinal herbs extract process |
CN103704483A (en) * | 2013-12-31 | 2014-04-09 | 株洲千金药业股份有限公司 | Feed fermented by utilizing traditional Chinese medicine drugs and preparation method of feed |
CN104523943A (en) * | 2014-12-29 | 2015-04-22 | 河南天纳图生物科技有限公司 | Compound fermentation type traditional Chinese medicine for preventing and treating multiple seasonal febrile diseases of livestock and poultry |
CN104983805A (en) * | 2015-07-21 | 2015-10-21 | 哈尔滨市龙生北药生物工程股份有限公司 | Preparation method of Pudilan anti-inflammatory tablet |
CN106361905A (en) * | 2016-08-30 | 2017-02-01 | 福建贝迪药业有限公司 | Compound Chinese herbal microecological preparation with efficacies of supporting right and resolving toxins for beasts and birds and preparation method of compound Chinese herbal microecological preparation |
CN106389562A (en) * | 2016-11-30 | 2017-02-15 | 河南牧翔动物药业有限公司 | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method |
CN106913516A (en) * | 2017-03-10 | 2017-07-04 | 南京安吉生物科技有限公司 | A kind of blue syrup in Pu ground and its production and use |
CN106913717A (en) * | 2017-03-10 | 2017-07-04 | 南京安吉生物科技有限公司 | The preparation method and purposes of a kind of Pu bring down a fever piece |
CN106913627A (en) * | 2017-03-20 | 2017-07-04 | 济川药业集团有限公司 | A kind of blue anti-inflammatory syrup in children Pu ground and preparation method thereof |
CN107319546A (en) * | 2017-08-07 | 2017-11-07 | 黑龙江省兽医科学研究所 | A kind of fermented tcm powder and preparation method thereof |
CN107889942A (en) * | 2017-12-04 | 2018-04-10 | 大工(青岛)新能源材料技术研究院有限公司 | Fermentative feedstuff of microbe and preparation method thereof |
CN109718269A (en) * | 2019-03-01 | 2019-05-07 | 江西农业大学 | A kind of Chinese medicine microecological preparation and preparation method thereof |
CN112237594A (en) * | 2019-07-18 | 2021-01-19 | 济川药业集团有限公司 | Pharmaceutical composition, Pudilan buccal tablet and preparation method thereof |
CN110663818A (en) * | 2019-08-23 | 2020-01-10 | 内蒙古农业大学 | Fermented dandelion feed additive and preparation method and application thereof |
WO2022022020A1 (en) * | 2020-07-30 | 2022-02-03 | 江苏康缘药业股份有限公司 | Traditional chinese medicine composition, preparation method and use |
Non-Patent Citations (6)
Title |
---|
反相高效液相色谱法测定蒲地蓝消炎片中黄芩苷的含量;席文胜;关小彬;张艳玲;;中国药房;20061230(第24期);第1899-1900页 * |
药物分析(Ⅰ);柴逸峰;朱臻宇;李翔;;分析试验室;20080801(第08期);第183-122页 * |
蒲公英发酵及对其粗提物中黄酮类物质含量的影响;宗凯;刘国庆;张黎利;金宇燕;潘炜铃;杨小娇;;农产品加工(创新版);20100228(第02期);第38-41页 * |
蒲地蓝消炎口服液治疗小儿风热咳嗽36例疗效观察;丁翠萍;陶蕾;;四川中医;20150115(第01期);第168-171页 * |
蒲地蓝胶囊的制备工艺研究;徐宁宁;;山东化工;20191223(第24期);第45-46页 * |
黄芪药材的发酵研究进展;徐荣芳;薛慧清;闫润红;李艳彦;郭羽;刘必旺;;山西中医学院学报;20120628(第03期);第140-142页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116898921A (en) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104288194B (en) | A kind of preparation method of compound isatis root granules | |
CN107595893A (en) | A kind of enzyme treated prepared slices of Chinese crude drugs and preparation method thereof | |
CN105410346A (en) | Cultured penaeus vannamei survival rate improving traditional Chinese medicine preparation and preparation method thereof | |
CN104946453A (en) | Preparation and use method of health drug wheat koji | |
CN101023972A (en) | Use of phenolic acids effective part in dandelion for treating stomatocace | |
CN108686045B (en) | Callicarpa nudiflora composition and application thereof in treating pharyngitis | |
CN108524685B (en) | Composition for treating children herpangina and application thereof | |
WO2020252757A1 (en) | Pharmaceutical composition for controlling african swine fever, and extraction, injection and use thereof | |
CN116898921B (en) | Preparation method of cattail and dyer woad compound traditional Chinese medicine preparation | |
CN112691138B (en) | Preparation method of mulberry resource extract with in-vitro inhibitory activity on African swine fever virus | |
WO2018099493A1 (en) | Tropaeolum majus granules and preparation method therefor | |
CN110251561B (en) | Antiviral compound traditional Chinese medicine preparation for pigs and preparation method thereof | |
CN1814166A (en) | Pulse-promoting powder injecta and preparing method | |
CN114668797B (en) | Plant fermentation liquid for resisting oxidation, reducing blood fat and protecting liver as well as preparation method and application thereof | |
CN110959858A (en) | Guiling jelly containing balsam pear juice and preparation method thereof | |
CN112121074B (en) | Compound plant extract preparation for preventing and controlling porcine viral diseases and application thereof | |
CN107823375A (en) | A kind of Chinese medicinal tablet for treating mastitis for milk cows and preparation method thereof | |
CN114344358A (en) | Eucommia ulmoides composition containing aucubin and geniposide, preparation and application | |
CN105250727A (en) | Traditional Chinese medicine composition for prevention and treatment of livestock diarrhea and preparation method of traditional Chinese medicine composition | |
CN1237998C (en) | Effervescence tablet for treating children's cough and asthma and its preparation | |
CN111249318A (en) | Hericium erinaceus culture medium for treating wind-heat type common cold, mulberry leaf and hericium erinaceus transformed mycelium, extract and application | |
CN118593566B (en) | A compound containing lotus stalk extract for promoting blood circulation and removing blood stasis, and its preparation method | |
CN115006355B (en) | Preparation method of veterinary coptis chinensis granules with full-component extraction | |
CN107951972A (en) | Apply medicinal lotion or ointment outside a kind of Chinese traditional medicine composition for treating mastitis for milk cows thing and preparation method thereof | |
CN106668081B (en) | High-activity drying method of golden ganoderma medicinal material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |